12:00 AM
 | 
Jul 09, 2012
 |  BC Week In Review  |  Company News  |  Other News

GlaxoSmithKline endocrine/metabolic, neurology news

GlaxoSmithKline finalized a $3 billion settlement with the U.S. government and will plead guilty to misdemeanor charges related to the marketing of antidepressants Paxil paroxetine and Wellbutrin bupropion and failure to report safety data to FDA for diabetes drug Avandia rosiglitazone....

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >